表紙
市場調查報告書

角膜乾燥症 (乾眼症) :開發中產品分析

Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 219724
出版日期 內容資訊 英文 320 Pages
訂單完成後即時交付
價格
角膜乾燥症 (乾眼症) :開發中產品分析 Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2020
出版日期: 2020年03月31日內容資訊: 英文 320 Pages
簡介

乾眼症症候群同時也被稱之為乾性角結膜炎(KCS)或乾燥角膜炎,是淚液及眼睛表面的多因子疾病。由於眼睛表面的潛在性損傷造成不適感、視覺障礙、淚液層不穩定性。常見的症狀有眼睛疲勞、畏光刺眼、充血等。危險因子除了年齡之外,還有可能因雷射眼科手術、藥劑等因素所造成。

本報告提供角膜乾燥症 (乾眼症) 的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

角膜乾燥症 (乾眼症)的概要

治療藥的開發

  • 開發中產品的概要

角膜乾燥症 (乾眼症) :企業開發中的治療藥

角膜乾燥症 (乾眼症) :開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

角膜乾燥症 (乾眼症) :企業開發中的產品

角膜乾燥症 (乾眼症)的治療藥的開發企業

  • AB2 Bio Ltd.
  • Akari Therapeutics, Plc
  • Allergan Plc
  • Circadian Technologies Limited
  • Delenex Therapeutics AG
  • Digna Biotech, S.L.
  • Dompe Farmaceutici S.p.A.
  • HanAll Biopharma Co., Ltd.
  • Herantis Pharma Plc
  • Huons Co., Ltd.
  • InSite Vision Incorporated
  • Kala Pharmaceuticals, Inc.
  • Kissei Pharmaceutical Co., Ltd.
  • Kukje Pharmaceutical Industry Co., Ltd.
  • Laboratorios Sophia S.A. de C.V.
  • Lee's Pharmaceutical Holdings Limited
  • Lipicard Technologies Limited
  • Merck & Co., Inc.
  • Mimetogen Pharmaceuticals Inc.
  • Mitotech S.A.
  • Nanomerics Ltd
  • Neuroptis Biotech
  • Novaliq GmbH
  • Ocular Therapeutix, Inc.
  • Oculis ehf
  • OncoNOx ApS
  • 大塚集團
  • Parion Sciences, Inc.
  • PharmaReaserch Products Co., Ltd.
  • RegeneRx Biopharmaceuticals, Inc.
  • Rigel Pharmaceuticals, Inc.
  • Samjin Pharmaceutical Co., Ltd.
  • 參天製藥
  • 生化學工業
  • Shire Plc
  • Sucampo Pharmaceuticals, Inc.
  • TearSolutions, LLC.
  • Xigen SA

角膜乾燥症 (乾眼症) :治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

角膜乾燥症 (乾眼症) :最近的開發平台趨勢

角膜乾燥症 (乾眼症) :暫停中的計劃

角膜乾燥症 (乾眼症) :開發中止的產品

角膜乾燥症 (乾眼症) :產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC12104IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keratoconjunctivitis Sicca - Pipeline Review, H1 2020, provides an overview of the Keratoconjunctivitis Sicca (Ophthalmology) pipeline landscape.

Keratoconjunctivitis sicca (KCS) or dry eye disease (DED) or dry eye syndrome (DES) is a condition in which a person experience desiccation of the conjunctiva and cornea due to an inadequate tear film. Symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia and blurry vision. Risk factors include age, wearing contact lenses and low levels of vitamin A. Treatment includes artificial tear substitutes, topical anti-inflammatory agents, secretagogues and immunosuppressants.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keratoconjunctivitis Sicca - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Keratoconjunctivitis Sicca (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keratoconjunctivitis Sicca (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratoconjunctivitis Sicca (Dry Eye) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 17, 29, 7, 1, 38, 6 and 5 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 2 and 1 molecules, respectively.

Keratoconjunctivitis Sicca (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis Sicca (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Keratoconjunctivitis Sicca (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Keratoconjunctivitis Sicca (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Keratoconjunctivitis Sicca (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Keratoconjunctivitis Sicca (Ophthalmology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Keratoconjunctivitis Sicca (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Keratoconjunctivitis Sicca (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
    • Keratoconjunctivitis Sicca (Dry Eye) - Overview
    • Keratoconjunctivitis Sicca (Dry Eye) - Therapeutics Development
    • Keratoconjunctivitis Sicca (Dry Eye) - Therapeutics Assessment
    • Keratoconjunctivitis Sicca (Dry Eye) - Companies Involved in Therapeutics Development
    • Keratoconjunctivitis Sicca (Dry Eye) - Drug Profiles
    • Keratoconjunctivitis Sicca (Dry Eye) - Dormant Projects
    • Keratoconjunctivitis Sicca (Dry Eye) - Discontinued Products
    • Keratoconjunctivitis Sicca (Dry Eye) - Product Development Milestones
    • Appendix

List of Tables

  • Number of Products under Development for Keratoconjunctivitis Sicca (Dry Eye), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by AB2 Bio Ltd, H1 2020
  • Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Abilita Bio Inc, H1 2020
  • Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Actinobac Biomed Inc, H1 2020
  • Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Aerie Pharmaceuticals Inc, H1 2020
  • Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Aldeyra Therapeutics Inc, H1 2020
  • Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Allegro Ophthalmics LLC, H1 2020
  • Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Allergan Plc, H1 2020
  • Keratoconjunctivitis Sicca (Dry Eye) - Dormant Projects, H1 2020
  • Keratoconjunctivitis Sicca (Dry Eye) - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Keratoconjunctivitis Sicca (Dry Eye), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020